Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma.
Neurohospitalist
; 8(4): 191-193, 2018 Oct.
Article
em En
| MEDLINE
| ID: mdl-30245770
ABSTRACT
Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Revista:
Neurohospitalist
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Austrália